5-Aminosalicylates Drugs Market
Number of pages: 100 | Report Format: PDF | Published date: May 16, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
CAGR |
3.5% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Indication, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global 5-aminosalicylates drugs market is expected to register a revenue CAGR of 3.5% during the forecast period.
5-Aminosalicylates Drugs Market Fundamentals
Aminosalicylates (5-ASAs) are a class of medications that reduce inflammation in the large and small intestines. For mild to severe ulcerative colitis, 5-ASAs are frequently the first-line therapy. They may also be used to sustain long-term symptom remission and avoid flare-ups of ulcerative colitis. Although 5-ASAs are less usually used to treat Crohn's disease, they may be useful in milder instances or to help control symptoms after surgery. Sulfasalazine or a 5-aminosalicylate must frequently be taken over an extended length of time. Side effects from these drugs might range from minor to severe. Sulfasalazine has far more frequent side effects. In general, 5-aminosalicylates are very well tolerated. The major adverse effects of these medications are infrequent or unusual, and they often go away when the prescription is stopped. Many of the minor side effects may be prevented by using lower dosages of them. Most of the time, these medications' potential advantages surpass any possible drawbacks. But before beginning therapy, it's critical to be informed of any potential adverse effects.
It is necessary to take sulfasalazine or a 5-aminosalicylate often over a lengthy period of time. These medications may have mild to severe side effects. The negative effects of sulfasalazine occur much more often. 5-Aminosalicylates are generally relatively well tolerated. These drugs' most severe side effects are uncommon or unique and frequently go away when the prescription is stopped. Lower doses of these may be used to avoid many of the mild adverse effects. The potential benefits of these drugs often outweigh any potential risks. However, it's essential to be aware of any potential side effects before starting therapy.
The global 5-aminosalicylates drugs industry market report comprehensively analyzes the market, with the factors that either aid or impede the market growth, such as its drivers, restraints, and opportunities. The research provides insight into the companies that operate in the 5-aminosalicylates drugs market and their efforts to position themselves as key players through expansion strategies and innovations. It also highlights recent developments that contribute to the 5-aminosalicylates drugs market growth. The research also analyzes the impact of the COVID-19 pandemic.
This research is valuable for businesses seeking insights into the market, customers, and competition. The research provides special insights into the segmentation, regions, market size & projection, revenue CAGRs, and other important information that may help clients make the right decisions. The report assembles data from market players and professionals across the industrial value chain. The study also incorporates qualitative and quantitative assessments from industry professionals. Secondary research, surveys and interviews, and statistical modeling are all used in our research to estimate market size and projection. Our reports deliver the most reliable market data because of our specialized research methods.
5-Aminosalicylates Drugs Market Dynamics
The market growth is predicted to be fueled by the increasing incidence of ulcerative colitis and Crohn's disease worldwide. Government measures to enhance healthcare for IBD patients have increased, as these individuals are more prone to contracting infections due to immunosuppressive medications.
The most prevalent inflammatory bowel illness, ulcerative colitis (UC), affects many people. According to a study by Whitney D. Lynch et al., published in June 2022, there are 9 to 20 cases of ulcerative colitis worldwide per 100,000 persons each year. Between 156 and 291 cases per 100,000 persons were reported annually. Adults are more likely to suffer from ulcerative colitis. The industry is anticipated to develop due to the increasing burden of this disease. More than 1.6 million Americans have ulcerative colitis or Crohn's disease, and 70,000 new instances of IBD are thought to be identified in the US each year, according to the Crohn's & Colitis Foundation of America. In addition, more than 80,000 people in Australia have IBD, according to the RAH Research Fund. All these factors are likey to boost the market growth for 5-aminosalicylates drugs market globally.
5-Aminosalicylates Drugs Market Ecosystem
5-aminosalicylates drugs market, by Type
5-aminosalicylates drugs market, by Indication
5-Aminosalicylates Drugs Market by Indication
[25412]
The ulcerative colitis market is predicted to develop at a profitable pace throughout the forecasted period due to a large patient population. Around 54% of IBD patients diagnosed in Europe and the United States had ulcerative colitis. Additionally, businesses are working together to meet the rising need for ulcerative colitis treatment medications. For example, Athos Therapeutics announced plans for a research partnership with Lahey Hospital and Medical Center in Burlington, Massachusetts, in July 2022, with the goal of developing precision medication for inflammatory bowel disease (IBD) and ulcerative colitis. Additionally, the introduction of new medications by various market participants is also accelerating the expansion of this market sector. For instance, Teva Pharmaceuticals USA, Inc. began selling its 1000 mg generic version of Casana (mesalamine), a suppository drug used to treat individuals with active ulcerative proctitis (ulcerative rectal colitis), in the United States in April 2021.
The market segmentation sections provide the 5-aminosalicylates drugs market outlook in terms of the demarcation of different consumer groups. Market segmentation is the splitting of an industry into subgroups depending on characteristics such as type and indication. Market segmentation data helps organizations understand the preferences and distinctive demands of different customer groups and implement targeted marketing strategies. This data additionally helps in identifying potential 5-aminosalicylates drugs market demand opportunities.
5-Aminosalicylates Drugs Market by Region
North America dominated the market for 5-aminosalicylates medicines globally due to the large number of powerful market players and the numerous strategic efforts they took in the region, Additionally, regional expansion is made possible by the region's improved healthcare practices, high treatment rates, and rising prescription of innovative treatments. The continued development of innovative treatments and supporting government policies are also expected to fuel the region's growth.
Over the projection period, Asia Pacific is expected to see the fastest growth. Some key reasons driving market expansion in the upcoming years include an aging population, a high chance of getting inflammatory illnesses, an increase in the incidence of inflammatory bowel disorders, and better healthcare policies in the area. Additionally, increased investments by top players in the field and the increasing acceptance of biosimilar and biologics are anticipated to fuel market expansion in the near future.
Based on the regions, the global 5-aminosalicylates drugs market is segmented into:
The industry's regional segmentation provides insights into geographic pockets in terms of 5-aminosalicylates drugs industry trends, market size, share, and growth rate. This information helps organizations assess potential growth opportunities in new regional markets, understand competitive threats, and develop localized sales and expansion strategies. This section also offers deeper insights into the regional and country-level 5-aminosalicylates drugs market overview.
Key Components of the Report
5-Aminosalicylates Drugs Market Competitive Landscape
The market competitive landscape analysis is performed by gathering and evaluating data about the key competitors, industry trends, and market dynamics. It involves collecting and analyzing data on factors such as products, pricing, geographic reach, customer demographics, marketing tactics, and recent developments. Competitive landscape analysis can help organizations identify present or prospective opportunities and risks in the market.
Reasons To Buy This Report
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Aminosalicylates (5-ASAs) are a class of medications that reduce inflammation in the large and small intestines. For mild to severe ulcerative colitis, 5-ASAs are frequently the first-line therapy. They may also be used to sustain long-term symptom remission and avoid flare-ups of ulcerative colitis. Although 5-ASAs are less usually used to treat Crohn's disease, they may be useful in milder instances or to help control symptoms after surgery.
North America region/country will have the largest 5-aminosalicylates drugs market size during the forecast period from 2023 to 2031.
The revenue CAGR in the global 5-aminosalicylates drugs market is expected to have around 3.5% during the forecast period.
The rising research and development and growing technological advancement are creating growth opportunities in the global 5-aminosalicylates drugs market.
The high levels of unmet clinical need in ulcerative colitis and the side effects of medications are key challenges that hamper the growth of the global 5-aminosalicylates drugs market.
To enhance their market share, major market players are implementing tactics including new product development, mergers, and acquisitions, and alliances are the major strategies adopted by key market players.
The high global incidence and prevalence of ulcerative colitis and Crohn’s disease are anticipated to fuel the growth.
Some prominent market players in the global 5-aminosalicylates drugs include Takeda Pharmaceutical Company Limited, Abbvie, Inc., and Tillotts Pharma AG.
The ulcerative colitis segment has the highest share in the global 5-aminosalicylates drugs market.
*Insights on financial performance are subject to the availability of information in the public domain